Glioblastomas are composed of genetically divergent clones with distinct tumourigenic potential and variable stem cell-associated phenotypes

Daniel Stieber, Anna Golebiewska, Lisa Evers, Elizabeth Lenkiewicz, Nicolaas H C Brons, Nathalie Nicot, Anaïs Oudin, Sébastien Bougnaud, Frank Hertel, Rolf Bjerkvig, Laurent Vallar, Michael Barrett, Simone P. Niclou

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Glioblastoma (GBM) is known to be a heterogeneous disease; however, the genetic composition of the cells within a given tumour is only poorly explored. In the advent of personalised medicine the understanding of intra-tumoural heterogeneity at the cellular and the genetic level is mandatory to improve treatment and clinical outcome. By combining ploidy-based flow sorting with array-comparative genomic hybridization we show that primary GBMs present as either mono- or polygenomic tumours (64 versus 36 %, respectively). Monogenomic tumours were limited to a pseudodiploid tumour clone admixed with normal stromal cells, whereas polygenomic tumours contained multiple tumour clones, yet always including a pseudodiploid population. Interestingly, pseudodiploid and aneuploid fractions carried the same aberrations as defined by identical chromosomal breakpoints, suggesting that evolution towards aneuploidy is a late event in GBM development. Interestingly, while clonal heterogeneity could be recapitulated in spheroid-based xenografts, we find that genetically distinct clones displayed different tumourigenic potential. Moreover, we show that putative cancer stem cell markers including CD133, CD15, A2B5 and CD44 were present on genetically distinct tumour cell populations. These data reveal the clonal heterogeneity of GBMs at the level of DNA content, tumourigenic potential and stem cell marker expression, which is likely to impact glioma progression and treatment response. The combined knowledge of intra-tumour heterogeneity at the genetic, cellular and functional level is crucial to assess treatment responses and to design personalized treatment strategies for primary GBM.

Original languageEnglish (US)
Pages (from-to)203-219
Number of pages17
JournalActa Neuropathologica
Volume127
Issue number2
DOIs
StatePublished - Feb 2014
Externally publishedYes

Fingerprint

Glioblastoma
Stem Cells
Clone Cells
Phenotype
Neoplasms
Aneuploidy
Precision Medicine
Comparative Genomic Hybridization
Genetic Heterogeneity
Neoplastic Stem Cells
Ploidies
Stromal Cells
Heterografts
Glioma
Population
Therapeutics
DNA

Keywords

  • Array CGH
  • Cancer stem cell
  • Clonal evolution
  • Flow cytometry
  • Glioma
  • Ploidy
  • Single cell array CGH

ASJC Scopus subject areas

  • Clinical Neurology
  • Pathology and Forensic Medicine
  • Cellular and Molecular Neuroscience

Cite this

Glioblastomas are composed of genetically divergent clones with distinct tumourigenic potential and variable stem cell-associated phenotypes. / Stieber, Daniel; Golebiewska, Anna; Evers, Lisa; Lenkiewicz, Elizabeth; Brons, Nicolaas H C; Nicot, Nathalie; Oudin, Anaïs; Bougnaud, Sébastien; Hertel, Frank; Bjerkvig, Rolf; Vallar, Laurent; Barrett, Michael; Niclou, Simone P.

In: Acta Neuropathologica, Vol. 127, No. 2, 02.2014, p. 203-219.

Research output: Contribution to journalArticle

Stieber, D, Golebiewska, A, Evers, L, Lenkiewicz, E, Brons, NHC, Nicot, N, Oudin, A, Bougnaud, S, Hertel, F, Bjerkvig, R, Vallar, L, Barrett, M & Niclou, SP 2014, 'Glioblastomas are composed of genetically divergent clones with distinct tumourigenic potential and variable stem cell-associated phenotypes', Acta Neuropathologica, vol. 127, no. 2, pp. 203-219. https://doi.org/10.1007/s00401-013-1196-4
Stieber, Daniel ; Golebiewska, Anna ; Evers, Lisa ; Lenkiewicz, Elizabeth ; Brons, Nicolaas H C ; Nicot, Nathalie ; Oudin, Anaïs ; Bougnaud, Sébastien ; Hertel, Frank ; Bjerkvig, Rolf ; Vallar, Laurent ; Barrett, Michael ; Niclou, Simone P. / Glioblastomas are composed of genetically divergent clones with distinct tumourigenic potential and variable stem cell-associated phenotypes. In: Acta Neuropathologica. 2014 ; Vol. 127, No. 2. pp. 203-219.
@article{15a5cadfdc324bd38367faa7c5ca3810,
title = "Glioblastomas are composed of genetically divergent clones with distinct tumourigenic potential and variable stem cell-associated phenotypes",
abstract = "Glioblastoma (GBM) is known to be a heterogeneous disease; however, the genetic composition of the cells within a given tumour is only poorly explored. In the advent of personalised medicine the understanding of intra-tumoural heterogeneity at the cellular and the genetic level is mandatory to improve treatment and clinical outcome. By combining ploidy-based flow sorting with array-comparative genomic hybridization we show that primary GBMs present as either mono- or polygenomic tumours (64 versus 36 {\%}, respectively). Monogenomic tumours were limited to a pseudodiploid tumour clone admixed with normal stromal cells, whereas polygenomic tumours contained multiple tumour clones, yet always including a pseudodiploid population. Interestingly, pseudodiploid and aneuploid fractions carried the same aberrations as defined by identical chromosomal breakpoints, suggesting that evolution towards aneuploidy is a late event in GBM development. Interestingly, while clonal heterogeneity could be recapitulated in spheroid-based xenografts, we find that genetically distinct clones displayed different tumourigenic potential. Moreover, we show that putative cancer stem cell markers including CD133, CD15, A2B5 and CD44 were present on genetically distinct tumour cell populations. These data reveal the clonal heterogeneity of GBMs at the level of DNA content, tumourigenic potential and stem cell marker expression, which is likely to impact glioma progression and treatment response. The combined knowledge of intra-tumour heterogeneity at the genetic, cellular and functional level is crucial to assess treatment responses and to design personalized treatment strategies for primary GBM.",
keywords = "Array CGH, Cancer stem cell, Clonal evolution, Flow cytometry, Glioma, Ploidy, Single cell array CGH",
author = "Daniel Stieber and Anna Golebiewska and Lisa Evers and Elizabeth Lenkiewicz and Brons, {Nicolaas H C} and Nathalie Nicot and Ana{\"i}s Oudin and S{\'e}bastien Bougnaud and Frank Hertel and Rolf Bjerkvig and Laurent Vallar and Michael Barrett and Niclou, {Simone P.}",
year = "2014",
month = "2",
doi = "10.1007/s00401-013-1196-4",
language = "English (US)",
volume = "127",
pages = "203--219",
journal = "Acta Neuropathologica",
issn = "0001-6322",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Glioblastomas are composed of genetically divergent clones with distinct tumourigenic potential and variable stem cell-associated phenotypes

AU - Stieber, Daniel

AU - Golebiewska, Anna

AU - Evers, Lisa

AU - Lenkiewicz, Elizabeth

AU - Brons, Nicolaas H C

AU - Nicot, Nathalie

AU - Oudin, Anaïs

AU - Bougnaud, Sébastien

AU - Hertel, Frank

AU - Bjerkvig, Rolf

AU - Vallar, Laurent

AU - Barrett, Michael

AU - Niclou, Simone P.

PY - 2014/2

Y1 - 2014/2

N2 - Glioblastoma (GBM) is known to be a heterogeneous disease; however, the genetic composition of the cells within a given tumour is only poorly explored. In the advent of personalised medicine the understanding of intra-tumoural heterogeneity at the cellular and the genetic level is mandatory to improve treatment and clinical outcome. By combining ploidy-based flow sorting with array-comparative genomic hybridization we show that primary GBMs present as either mono- or polygenomic tumours (64 versus 36 %, respectively). Monogenomic tumours were limited to a pseudodiploid tumour clone admixed with normal stromal cells, whereas polygenomic tumours contained multiple tumour clones, yet always including a pseudodiploid population. Interestingly, pseudodiploid and aneuploid fractions carried the same aberrations as defined by identical chromosomal breakpoints, suggesting that evolution towards aneuploidy is a late event in GBM development. Interestingly, while clonal heterogeneity could be recapitulated in spheroid-based xenografts, we find that genetically distinct clones displayed different tumourigenic potential. Moreover, we show that putative cancer stem cell markers including CD133, CD15, A2B5 and CD44 were present on genetically distinct tumour cell populations. These data reveal the clonal heterogeneity of GBMs at the level of DNA content, tumourigenic potential and stem cell marker expression, which is likely to impact glioma progression and treatment response. The combined knowledge of intra-tumour heterogeneity at the genetic, cellular and functional level is crucial to assess treatment responses and to design personalized treatment strategies for primary GBM.

AB - Glioblastoma (GBM) is known to be a heterogeneous disease; however, the genetic composition of the cells within a given tumour is only poorly explored. In the advent of personalised medicine the understanding of intra-tumoural heterogeneity at the cellular and the genetic level is mandatory to improve treatment and clinical outcome. By combining ploidy-based flow sorting with array-comparative genomic hybridization we show that primary GBMs present as either mono- or polygenomic tumours (64 versus 36 %, respectively). Monogenomic tumours were limited to a pseudodiploid tumour clone admixed with normal stromal cells, whereas polygenomic tumours contained multiple tumour clones, yet always including a pseudodiploid population. Interestingly, pseudodiploid and aneuploid fractions carried the same aberrations as defined by identical chromosomal breakpoints, suggesting that evolution towards aneuploidy is a late event in GBM development. Interestingly, while clonal heterogeneity could be recapitulated in spheroid-based xenografts, we find that genetically distinct clones displayed different tumourigenic potential. Moreover, we show that putative cancer stem cell markers including CD133, CD15, A2B5 and CD44 were present on genetically distinct tumour cell populations. These data reveal the clonal heterogeneity of GBMs at the level of DNA content, tumourigenic potential and stem cell marker expression, which is likely to impact glioma progression and treatment response. The combined knowledge of intra-tumour heterogeneity at the genetic, cellular and functional level is crucial to assess treatment responses and to design personalized treatment strategies for primary GBM.

KW - Array CGH

KW - Cancer stem cell

KW - Clonal evolution

KW - Flow cytometry

KW - Glioma

KW - Ploidy

KW - Single cell array CGH

UR - http://www.scopus.com/inward/record.url?scp=84896697126&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896697126&partnerID=8YFLogxK

U2 - 10.1007/s00401-013-1196-4

DO - 10.1007/s00401-013-1196-4

M3 - Article

C2 - 24154962

AN - SCOPUS:84896697126

VL - 127

SP - 203

EP - 219

JO - Acta Neuropathologica

JF - Acta Neuropathologica

SN - 0001-6322

IS - 2

ER -